Ken Newport
Board of Directors @ OPMEDIC
Ken Newport is a angel investor at OPMEDIC focused on Life Science and Biotechnology. Ken Newport was appointed to Jennerex's board in 2007. A chartered accountant, entrepreneur and life sciences business executive, Mr. Newport served as senior vice president and executive committee member at PRA International Inc. for three years until his retirement in 2005. In the mid-nineties he was co-founder and president of CroMedicaInc., a clinical trials contract research organization which was sold to PRA International in 2002. Mr. Newport was also a founding member of Global Biomedical Capital Corporation, Zelos Therapeutics Inc., Prime Trials Inc. and other life science organizations. He is a member of the Institute of Corporate Directors and also serves on the corporate boards of The Opmedic Group and Medgenesis Therapeutics Inc. Mr. Newport earned Honours B.A. and Masters of Accounting degrees from the University of Waterloo.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Ken Newport invests in
Stages Ken Newport invests in
Countries Ken Newport invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Life Science 1 (100%)
- Biotechnology 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rhythm Biotherapeutics
|
Rhythm Biotherapeutics is a preclinical-stage firm that aims to solve a key unmet need by preventing and treating atrial fibrillation, a chronic, progressive, debilitating, and life-threatening condition. Our initial focus is on a preventative solution for postoperative atrial fibrillation. RBex is a preventive exosome treatment that has shown an87% reduction in postoperative atrial fibrillation in comprehensive and published preclinical trials. We are now soliciting funds to conduct a first-in-human phase 1 clinical trial. | $235K / Angel / Jan 01, 2023 |
About OPMEDIC
OPMEDIC Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Ken Newport
Board of Directors
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Ken Newport invest in?
Ken Newport invests primarily in Life Science and Biotechnology startups, most often at Angel stage. Most of the 1 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ken Newport?
Public channels for Ken Newport include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ken Newport last invest?
The most recent investment recorded for Ken Newport closed in Jan 2023. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
